Posted by Michael Wonder on 02 Feb 2018
Protalix BioTherapeutics’ pegunigalsidase alfa receives fast track designation from the U.S. FDA
31 January 2018 - Fast Track designation highlights high unmet medical need in the treatment of Fabry disease.
Prolix BioTherapeutics announced that the U.S. FDA has granted fast track designation to pegunigalsidase alfa, or PRX-102, the Company’s plant cell-expressed recombinant, pegylated, cross-linked α-galactosidase-A candidate for the treatment of Fabry disease.
Pegunigalsidase alfa is currently being studied globally in three phase III clinical trials. Enrollment in each of the trials continues to progress and estimated timelines for top-line data announcements will be announced upon completion of enrollment for each individual trial.
